Search PubMed⌕ Search

Biomedical subjects

D B Sharma

Publications and source records attributed to D B Sharma.

At least 19 recordsLinked to original sources

Quality of life after peptic perforation.

AIM OF STUDY: Quality of life (QOL) as outcome during treatment of acid peptic disease has been studied, but, peptic perforation, which is the commonest complication of acid peptic disease, has not been studied in the light of QOL outcome. The present-study addresses the important issue of QOL after peptic perforations. METHODS: This prospective study was carried on 51 adult consecutive survivors of peptic perforation managed in Gastrointestinal Surgery Unit, Department of Surgery, Government NSCB Medical College and Hospital, Jabalpur (MP) India. These underwent exploratory laparotomy with repair of perforation, and subsequently were discharged on anti-ulcer therapy (Pantoprazole 40 mg once a day) for 6 weeks. The instrument chosen to study their QOL was gastrointestinal quality of life index (GIQLI). Patients were assessed before they underwent surgery and 3 months and 6 months after operation. RESULTS: The overall GIQLI score (t = 20.1, p < 0.00 at 3 months; t = 8.2, p < 0.001 at 6 months) as well as its G I core (t = 14.5, p < 0.001 at 3 months; t = 7.3, p < 0.001 at 6 months), G I disease specific (t = 12.9, p < 0.001 at 3 months; t = 2.6, p < 0.02 at 6 months), psychological (t = 15.4, p < 0.001 at 3 months; t = 3.5, p < 0.001 at 6 months) and physical and social components (t = 10.9, p < 0.001 at 3 months; t = 4.2, p < 0.001 at 6 months) significantly increased over 3 and 6 months of follow-up, reflecting improvement in quality of life as perceived by the patients. Variations in the pattern of recovery, based on age and gender were not seen in the present study. CONCLUSION: Peptic perforation does not result in any long lasting impairment of QOL and the QOL improves to near normal in 6 months time after the perforation.

2-Pyridinylmethylsulfinylbenzimidazoles↗

Pharmacokinetics of carbamazepine in protein energy malnutrition.

The pharmacokinetics of carbamazepine was studied in 6 children with protein energy malnutrition (PEM) and in 6 healthy children. Plasma carbamazepine was estimated by enzyme multiplied immunoassay technique. Single-dose concentration profiles after 10 mg/kg of the drug showed lower plasma peak levels. The systemic availability (AUC 0-48 h) of the drug in PEM was also reduced. Based on these observations, suggestions have been made for rescheduling the dosage of the drug in PEM.

Adolescent↗

Pharmacokinetics of phenobarbitone in protein energy malnutrition.

Phenobarbitone kinetics was studied in malnourished and normal children after single oral dose of approximately 7.0 mg/kg. Estimation of serum phenobarbitone concentration was performed by spectrophotometric method. Elimination half-life was 58.9 +/- 9.5 h and 30.15 +/- 6.1 h for malnourished and healthy children, respectively. Compared to healthy children, tmax was prolonged in malnutrition group suggesting slow absorption in the latter group. The systemic bioavailability was observed to be higher in protein energy malnutrition. Modifications of the usual dosage regimen in malnutrition are recommended.

Absorption↗

Hepatoblastoma.

Explore the source record for details and available documents.

Carcinoma, Hepatocellular↗